Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP) : a sequential explanatory mixed-methods pilot study
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To gain insight into formal methods of integrating patient preferences and clinical evidence to inform treatment decisions, we explored patients' experience with a personalised decision analysis intervention, for prophylactic low-molecular-weight heparin (LMWH) in the antenatal period.
DESIGN: Mixed-methods explanatory sequential pilot study.
SETTING: Hospitals in Canada (n=1) and Spain (n=4 sites). Due to the COVID-19 pandemic, we conducted part of the study virtually.
PARTICIPANTS: 15 individuals with a prior venous thromboembolism who were pregnant or planning pregnancy and had been referred for counselling regarding LMWH.
INTERVENTION: A shared decision-making intervention that included three components: (1) direct choice exercise; (2) preference elicitation exercises and (3) personalised decision analysis.
MAIN OUTCOME MEASURES: Participants completed a self-administered questionnaire to evaluate decision quality (decisional conflict, self-efficacy and satisfaction). Semistructured interviews were then conducted to explore their experience and perceptions of the decision-making process.
RESULTS: Participants in the study appreciated the opportunity to use an evidence-based decision support tool that considered their personal values and preferences and reported feeling more prepared for their consultation. However, there were mixed reactions to the standard gamble and personalised treatment recommendation. Some participants could not understand how to complete the standard gamble exercises, and others highlighted the need for more informative ways of presenting results of the decision analysis.
CONCLUSION: Our results highlight the challenges and opportunities for those who wish to incorporate decision analysis to support shared decision-making for clinical decisions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
BMJ evidence-based medicine - 28(2023), 5 vom: 01. Okt., Seite 309-319 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Humphries, Brittany [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anticoagulants |
---|
Anmerkungen: |
Date Completed 25.09.2023 Date Revised 28.09.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1136/bmjebm-2022-112098 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM35364787X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM35364787X | ||
003 | DE-627 | ||
005 | 20231226060506.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1136/bmjebm-2022-112098 |2 doi | |
028 | 5 | 2 | |a pubmed24n1178.xml |
035 | |a (DE-627)NLM35364787X | ||
035 | |a (NLM)36858800 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Humphries, Brittany |e verfasserin |4 aut | |
245 | 1 | 0 | |a Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP) |b a sequential explanatory mixed-methods pilot study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.09.2023 | ||
500 | |a Date Revised 28.09.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. | ||
520 | |a OBJECTIVES: To gain insight into formal methods of integrating patient preferences and clinical evidence to inform treatment decisions, we explored patients' experience with a personalised decision analysis intervention, for prophylactic low-molecular-weight heparin (LMWH) in the antenatal period | ||
520 | |a DESIGN: Mixed-methods explanatory sequential pilot study | ||
520 | |a SETTING: Hospitals in Canada (n=1) and Spain (n=4 sites). Due to the COVID-19 pandemic, we conducted part of the study virtually | ||
520 | |a PARTICIPANTS: 15 individuals with a prior venous thromboembolism who were pregnant or planning pregnancy and had been referred for counselling regarding LMWH | ||
520 | |a INTERVENTION: A shared decision-making intervention that included three components: (1) direct choice exercise; (2) preference elicitation exercises and (3) personalised decision analysis | ||
520 | |a MAIN OUTCOME MEASURES: Participants completed a self-administered questionnaire to evaluate decision quality (decisional conflict, self-efficacy and satisfaction). Semistructured interviews were then conducted to explore their experience and perceptions of the decision-making process | ||
520 | |a RESULTS: Participants in the study appreciated the opportunity to use an evidence-based decision support tool that considered their personal values and preferences and reported feeling more prepared for their consultation. However, there were mixed reactions to the standard gamble and personalised treatment recommendation. Some participants could not understand how to complete the standard gamble exercises, and others highlighted the need for more informative ways of presenting results of the decision analysis | ||
520 | |a CONCLUSION: Our results highlight the challenges and opportunities for those who wish to incorporate decision analysis to support shared decision-making for clinical decisions | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a clinical decision-making | |
650 | 4 | |a haematology | |
650 | 4 | |a maternal medicine | |
650 | 4 | |a methods | |
650 | 4 | |a thromboembolism | |
650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
650 | 7 | |a Anticoagulants |2 NLM | |
700 | 1 | |a León-García, Montserrat |e verfasserin |4 aut | |
700 | 1 | |a Bates, Shannon M |e verfasserin |4 aut | |
700 | 1 | |a Guyatt, Gordon |e verfasserin |4 aut | |
700 | 1 | |a Eckman, M H |e verfasserin |4 aut | |
700 | 1 | |a D'Souza, Rohan |e verfasserin |4 aut | |
700 | 1 | |a Shehata, Nadine |e verfasserin |4 aut | |
700 | 1 | |a Jack, Susan M |e verfasserin |4 aut | |
700 | 1 | |a Alonso-Coello, Pablo |e verfasserin |4 aut | |
700 | 1 | |a Xie, Feng |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMJ evidence-based medicine |d 2018 |g 28(2023), 5 vom: 01. Okt., Seite 309-319 |w (DE-627)NLM279942753 |x 2515-4478 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2023 |g number:5 |g day:01 |g month:10 |g pages:309-319 |
856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjebm-2022-112098 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 28 |j 2023 |e 5 |b 01 |c 10 |h 309-319 |